Internal Medicine, Rheumatology · Clermont, FL
NPI
1225374085
Since 2012
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
2611 S US Hwy 27
Clermont, FL, 34711
Phone (352) 717-0603
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
252,654 services
Medicare patients, 2024
519
Average age 73
Drug cost, 2024
$3.9M
3,972 prescriptions
Company payments, 2025
$4,777
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Priya Prakash was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 113,600 times for 44 patients. In total Priya Prakash billed 252,654 services in 37 codes, and Medicare paid $2.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-11-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 113,600 | 44 | $3.60 | $409K |
| J3262 Injection, tocilizumab, 1 mg | Office | 56,120 | 17 | $4.70 | $264K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 36,330 | 35 | $8.31 | $302K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 12,550 | 26 | $30.93 | $388K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 8,100 | 12 | $9.05 | $73K |
| J0897 Injection, denosumab, 1 mg | Office | 7,740 | 76 | $20.56 | $159K |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 3,760 | 15 | $15.89 | $60K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 2,760 | 57 | $0.10 | $283 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,775 | 27 | $0.23 | $403 |
| 99214 Office E&M - Established | Office | 951 | 411 | $91.01 | $87K |
| 96401 Chemotherapy Administration | Office | 910 | 80 | $52.97 | $48K |
| 96413 Chemotherapy Administration | Office | 476 | 102 | $94.11 | $45K |
| 96415 Chemotherapy Administration | Office | 223 | 31 | $20.88 | $4,655 |
| 96372 Injection Administration | Office | 205 | 128 | $10.77 | $2,209 |
| 96375 Injection Administration | Office | 186 | 30 | $11.49 | $2,136 |
By year: 2022 $779K for 80,168 services; 2023 $1.4M for 157,417 services; 2024 $2.0M for 252,654 services.
Medicare prescription drug claims, 2024
In 2024, the drug Priya Prakash prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 569 prescriptions and refills. In total Priya Prakash wrote 3,972 Medicare prescriptions that cost $3.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 569 | 1,153 | 177 | $12K |
| Gabapentin Generic | 388 | 645 | 126 | $5,495 |
| Hydroxychloroquine Sulfate Generic | 343 | 840 | 123 | $12K |
| Celecoxib Generic | 342 | 541 | 118 | $20K |
| Prednisone Generic | 250 | 295 | 97 | $1,196 |
| Leflunomide Generic | 238 | 534 | 82 | $15K |
| Duloxetine Hcl Generic | 188 | 395 | 72 | $4,383 |
| Alendronate Sodium Generic | 147 | 346 | 56 | $1,234 |
| Meloxicam Generic | 145 | 245 | 54 | $459 |
| Folic Acid Generic | 126 | 334 | 56 | $773 |
| Humira(Cf) Pen Adalimumab | 106 | 116 | 15 | $1.1M |
| Sulfasalazine Generic | 98 | 175 | 29 | $1,920 |
| Naproxen Generic | 61 | 76 | 22 | $463 |
| Allopurinol Generic | 54 | 153 | 21 | $577 |
| Methotrexate Sodium Methotrexate Sodium/Pf | 51 | 66 | 16 | $646 |
Brand drugs: - claims; generic drugs: 3,242 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Priya Prakash $4,777 ($4,777 in general payments such as food, travel and fees) from 20 companies. The largest payer was Amgen Inc. with $955.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 64 | $955 |
| Abbvie Inc. ABBV | 31 | $710 |
| UCB, Inc. UCB.BR | 32 | $618 |
| Pfizer Inc. PFE | 20 | $352 |
| E.R. Squibb & Sons, L.L.C. BMY | 15 | $323 |
| Janssen Biotech, Inc. JNJ | 14 | $309 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $230 |
| Novartis Pharmaceuticals Corporation NVS | 16 | $224 |
| GlaxoSmithKline, LLC. GSK | 15 | $202 |
| Organon LLC OGN | 8 | $161 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.